Malaysian marketing deal for GeneMedix
UK-based biopharmaceutical firm GeneMedix has entered into two separatedeals with Hovid SDN BhD, one of Malaysia's leading pharmaceutical manufacturers.
Under a sales and distribution agreement, Hovid has been appointed as exclusive distributor and marketer of GeneMedix' products within Malaysia and other countries making up the Association of South East Asian Nations.
Under a separate manufacturing agreement, Hovid will also carry out vialling and packaging operations for the UK firm's first three products, namely granulocyte macrophage-colony stimulating factor, erythropoietin and interferon-alpha. The Malaysian firm will commence the design and construction of a purpose-built, state-of-the-art manufacturing facility immediately. This is expected to be completed in late-2001, with the first sales in the region expected in early-2003.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze